Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis

被引：0
|
作者：
Rule, Simon
Dreyling, Martin
Goy, Andre
Hess, Georg
Auer, Rebecca
Kahl, Brad S.
Hernandez-Rivas, Jose Angel
Londhe, Anil
Clow, Fong
Deshpande, Sanjay
Parisi, Lori
Wang, Michael
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
151
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis
    Rule, Simon
    Dreyling, Martin
    Goy, Andre
    Hess, Georg
    Auer, Rebecca
    Kahl, Brad
    Hernandez-Rivas, Jose-Angel
    Qi, Keqin
    Deshpande, Sanjay
    Parisi, Lori
    Wang, Michael
    HAEMATOLOGICA, 2019, 104 (05) : E211 - E214
  • [2] Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up
    Dreyling, Martin
    Goy, Andre
    Hess, Georg
    Kahl, Brad S.
    Hernandez-Rivas, Jose-Angel
    Schuier, Natasha
    Qi, Keqin
    Deshpande, Sanjay
    Zhu, Angeline
    Parisi, Lori
    Wang, Michael L.
    HEMASPHERE, 2022, 6 (05):
  • [3] Ibrutinib for relapsed/refractory mantle cell lymphoma: 7-year experience
    Grilo, I. T.
    Couto, M. E.
    Freitas, J. F.
    Pereira, D. P.
    Moreira, C.
    Chacim, S.
    Domingues, N.
    Santo, A. E.
    Martins, A.
    Viterbo, L.
    Oliveira, I.
    Moreira, I.
    Mariz, J. M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma
    Lee, Yong-Pyo
    Jung, Ye Ji
    Cho, Junhun
    Ko, Young Hyeh
    Kim, Won Seog
    Kim, Seok Jin
    Yoon, Sang Eun
    BLOOD RESEARCH, 2023, 58 (04) : 208 - 220
  • [5] Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up
    Rule, Simon
    Dreyling, Martin H.
    Goy, Andre
    Hess, Georg
    Auer, Rebecca
    Kahl, Brad S.
    Angel Hernandez-Rivas, Jose
    Qi, Keqin
    Deshpande, Sanjay
    Parisi, Lori
    Wang, Michael L.
    BLOOD, 2019, 134
  • [6] Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)
    Jain, Preetesh
    Romaguera, Jorge
    Srour, Samer A.
    Lee, Hun J.
    Hagemeister, Frederick
    Westin, Jason
    Fayad, Luis
    Samaniego, Felipe
    Badillo, Maria
    Zhang, Liang
    Nastoupil, Lorreta
    Kanagal-Shamanna, Rashmi
    Fowler, Nathan
    Wang, Michael L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (03) : 404 - 411
  • [7] The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma
    Tucker, David
    Morley, Nick
    MacLean, Peter
    Vandenberghe, Elisabeth
    Parisi, Lori
    Rule, Simon
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (06) : 1035 - 1038
  • [8] Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Michael
    Rule, Simon
    Zinzani, Pier Luigi
    Goy, Andre
    Casasnovas, Olivier
    Smith, Stephen D.
    Damaj, Gandhi
    Doorduijn, Jeanette K.
    Lamy, Thierry
    Morschhauser, Franck
    Panizo, Carlos
    Shah, Bijal D.
    Davies, Andrew
    Eek, Richard
    Dupuis, Jehan
    Jacobsen, Eric
    Kater, Arnon P.
    Gouill, Steven L. E.
    Oberic, Lucie
    Robak, Tadeusz
    Dua, Richa
    Frigault, Melanie M.
    Izumi, Raquel
    Nguyen, Dorothy
    Patel, Priti
    Yin, Ming
    Jurczak, Wojciech
    BLOOD, 2018, 132
  • [9] Long-Term Follow-Up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Michael
    Rule, Simon
    Zinzani, Pier Luigi
    Goy, Andre
    Casasnovas, Oliver
    Smith, Stephen
    Damaj, Gandhi
    Doorduijn, Jeanette K.
    Lamy, Thierry
    Morschhauser, Franck
    Panizo, Carlos
    Shah, Bijal
    Davies, Andrew
    Eek, Richard
    Dupuis, Jehan
    Jacobsen, Eric
    Kater, Arnon P.
    Le Gouill, Steven
    Oberic, Lucie
    Robak, Tadeusz
    Dua, Richa
    Frigault, Melanie M.
    Izumi, Raquel
    Nguyen, Dorothy
    Patel, Priti
    Yin, Ming
    Jurczak, Wojciech
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S316 - S316
  • [10] ECONOMIC EVALUATION OF IBRUTINIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA IN MEXICO
    Carlos, F.
    Herrera, M.
    Salazar, A.
    Aguirre, A.
    Gonzalez-Michaca, L.
    VALUE IN HEALTH, 2016, 19 (03) : A249 - A249
12345